Shares of Eli Lilly surged today after investigators spelled out the encouraging solanezumab data they plucked out of a secondary analysis of a group of patients with a mild form of the memory-wasting disease.
As Lilly ($LLY) conceded earlier, both of its late-stage studies for solanezumab failed to produce a statistically significant response for mild-to-moderate patients on two key endpoints. Simply put, the study failed. But after a secondary analysis of the first study showed that there was a 42% reduction in the rate of cognitive decline among a subpopulation of patients in the solanezumab arm with only a mild form of the disease, investigators decided to hunt for confirmation of that endpoint in a second Phase III. They didn't find it, seeing the numbers fall short of statistical significance after switching from one measure (ADAS- Cog11) to another (ADAS-Cog14). But by "pooling" the data they came up with a 34% reduction in cognitive decline in that particular group. None of the data indicated a significant reduction in the rate of functional decline.
The independent analyses of the EXPEDITION study data was conducted by the Alzheimer's Disease Cooperative Study, an academic research consortium and presented at the annual meeting of the American Neurological Association. Solanezumab is designed to reduce levels of beta amyloid, a toxic protein that accumulates in the brains of Alzheimer's patients.
Eli Lilly execs pushed hard to assert that the data represented an encouraging advance in the field, which has been blighted by a string of high-profile failures. But in the drug development world, data derived from secondary analysis is considered a notoriously unreliable gauge of efficacy. Lilly's second study produced evidence of only a weak response among mild patients, conflicting with the response seen in the first study. In the world of clinical drug development, Lilly has only demonstrated that it detected a weak signal in a particular subpopulation.
Lilly's investigators, as well as patient groups desperate for some sign of progress, highlighted the positive.
"Alzheimer's disease research has been extremely challenging," said Rachelle Doody, a professor at Baylor. "The data results from the solanezumab Phase III trials were encouraging to the ADCS team. These results represent an important step for the medical, academic, and scientific communities in understanding brain amyloid as a target of AD therapies."
Lilly execs agreed, "Our next step is to talk to the regulators to see what this means, although we think this is a step forward in getting to a treatment for Alzheimer's," David Ricks, president of Lilly Bio-Medicines, told The Wall Street Journal.
That sentiment helped drive up Lilly shares 5% this afternoon as investors bet on the first encouraging sign of success in years of expensive studies.
The $60 billion question here is whether Eli Lilly and its science team has the kind of data indicating that they are on a solid path to an approval. The likely answer is they don't and will have to gamble on at least one more big study to put this theory to the test again. Another potentially complicating fact: Investigators found that patients in the drug arm experienced a significantly higher risk of angina.
"This isn't the home run that is going to get you a medication by the end of the year, but it is very encouraging because with subsequent studies this could be a viable therapeutic option," Maria Carrillo, the VP of medical and scientific relations at the Alzheimer's Association, tells Bloomberg. "We need more options for our patients and families. We are very encouraged by what this could mean."
Special Report: The Alzheimer's pipeline: What's next?
Related conversation on Twitter :
Is Lilly's solanezumab a bust or a clear candidate for Phase III? Experts debate the path forward in light of new Alzheimer's data.
Started by @JohnCFierce